These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 16741372

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [IgA nephropathy: from predicting progression to treatment].
    Rauta V, Grönhagen-Riska C.
    Duodecim; 2006; 122(2):215-22. PubMed ID: 16509071
    [No Abstract] [Full Text] [Related]

  • 3. [Immunoglobulin A nephropaty: clinical practice guidelines].
    Fayad A, Robaina Sindin J, Calvo Abeucci M, Trimarchi H, Vázquez V.
    Medicina (B Aires); 2011; 71 Suppl 2():1-26. PubMed ID: 21903506
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The treatment of IgA nephropathy: status at the end of the millenium.
    Glassock RJ.
    J Nephrol; 1999; 12(5):288-96. PubMed ID: 10630691
    [Abstract] [Full Text] [Related]

  • 7. [IgA nephropathy (immunoglobulin A nephropathy, M.Berger). Main symptoms: (painless) macrohematuria or microhematuria].
    Kolyvanos Naumann U, Käser L, Vetter W.
    Praxis (Bern 1994); 2004 Oct 27; 93(44):1809-13; quiz 1814. PubMed ID: 15559904
    [No Abstract] [Full Text] [Related]

  • 8. The CARI guidelines. Prevention of progression of kidney disease.
    Harris D, Thomas M, Johnson D, Nicholls K, Gillin A, Caring for Australasians with Renal Impairment (CARI).
    Nephrology (Carlton); 2006 Apr 27; 11 Suppl 1():S2-197. PubMed ID: 16684077
    [No Abstract] [Full Text] [Related]

  • 9. [Management of IgA nephropathy].
    Amoroso L, De Sanctis L, Cappelli P, Di Vito R, Sirolli V, Bonomini M.
    G Ital Nefrol; 2011 Apr 27; 28(6):622-32. PubMed ID: 22167613
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [IgA nephropathy].
    Alamartine E.
    Rev Prat; 2003 Nov 30; 53(18):2023-6. PubMed ID: 15008216
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pediatric IgA nephropathy: clinical and therapeutic perspectives.
    Coppo R.
    Semin Nephrol; 2008 Jan 30; 28(1):18-26. PubMed ID: 18222343
    [Abstract] [Full Text] [Related]

  • 15. Immunoglobulin A nephropathy: fish oils and beyond.
    Feehally J.
    Curr Opin Nephrol Hypertens; 1996 Sep 30; 5(5):442-6. PubMed ID: 8937814
    [Abstract] [Full Text] [Related]

  • 16. IgA nephropathy treatment 25 years on: can we halt progression? The evidence base.
    Ballardie FW.
    Nephrol Dial Transplant; 2004 May 30; 19(5):1041-6. PubMed ID: 15102965
    [No Abstract] [Full Text] [Related]

  • 17. [IgA nephropathy--pathogenesis, pathophysiology, and therapy].
    Narita I, Goto S, Kondo D, Sakatsume M, Gejyo F.
    Nihon Rinsho; 2006 Feb 30; 64 Suppl 2():397-402. PubMed ID: 16523921
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of IgA nephropathy: an update.
    Rosselli JL, Thacker SM, Karpinski JP, Petkewicz KA.
    Ann Pharmacother; 2011 Oct 30; 45(10):1284-96. PubMed ID: 21954446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.